Premium Nahrungsergänzungsmittel | artgerecht

Amyloid Beta – Definition, Function and Alzheimer

Amyloid beta (Aβ) is a protein fragment naturally produced in the brain. Its abnormal accumulation forms plaques linked to Alzheimer disease and neurodegeneration.

Regular tips about health Regular tips about health

Things worth knowing about "Amyloid Beta"

Amyloid beta (Aβ) is a protein fragment naturally produced in the brain. Its abnormal accumulation forms plaques linked to Alzheimer disease and neurodegeneration.

What is Amyloid Beta?

Amyloid beta (also written as amyloid-beta or Aβ) is a small protein fragment produced naturally in the human brain. It is generated through the cleavage of a larger precursor protein known as the amyloid precursor protein (APP). Under healthy conditions, amyloid beta is continuously produced and cleared. However, in certain diseases – most notably Alzheimer disease – this balance breaks down, leading to the accumulation of amyloid beta fragments that form toxic deposits in the brain.

Formation and Biochemistry

The amyloid precursor protein (APP) is a transmembrane protein anchored in the cell membrane of neurons. It is cleaved by enzymes called secretases, and there are two main processing pathways:

Non-amyloidogenic pathway: Alpha-secretase cleaves APP in a way that prevents full-length amyloid beta from being produced. This pathway is considered neuroprotective.
Amyloidogenic pathway: Beta- and gamma-secretase cleave APP to release amyloid beta fragments – in particular Aβ40 and the more aggregation-prone and toxic Aβ42. Aβ42 has a strong tendency to aggregate into insoluble plaques.

Role in Alzheimer Disease

The accumulation of amyloid beta plaques in the brain is one of the defining hallmarks of Alzheimer disease. According to the widely accepted amyloid cascade hypothesis, the excessive production or insufficient clearance of Aβ triggers a cascade of damaging events:

Formation of insoluble amyloid plaques between neurons
Triggering of neuroinflammatory responses in brain tissue
Disruption of synaptic transmission and neuronal communication
Promotion of tau protein aggregation into neurofibrillary tangles inside neurons
Progressive neuronal death and brain tissue atrophy (neurodegeneration)

Diagnosis and Detection Methods

Amyloid beta can be detected in living patients through several methods:

Cerebrospinal fluid (CSF) analysis: A reduced Aβ42 level in the CSF is a characteristic sign of increased plaque deposition in the brain, as the protein becomes trapped in plaques rather than circulating freely.
Amyloid PET (positron emission tomography): A brain imaging technique in which radioactively labeled tracers bind specifically to amyloid plaques, making them visible on the scan.
Blood-based biomarkers: Emerging research shows that the Aβ42/Aβ40 ratio in blood plasma may serve as an early diagnostic marker for Alzheimer disease.

Therapeutic Approaches

Reducing amyloid beta burden in the brain is a central goal of Alzheimer research. Several therapeutic strategies are being pursued:

Anti-amyloid antibodies (immunotherapy): Monoclonal antibodies such as lecanemab and donanemab are designed to clear amyloid plaques from the brain. Clinical trials have shown a slowing of cognitive decline in patients with early-stage Alzheimer disease.
Secretase inhibitors: Compounds that block beta- or gamma-secretase activity to reduce Aβ production. Many of these approaches have shown limited efficacy or significant side effects in clinical trials.
Aggregation inhibitors: Substances that aim to prevent the clustering of Aβ fragments into plaques.

Significance in Research

Amyloid beta is one of the most extensively studied biomarkers in neuroscience. While the amyloid cascade hypothesis remains the dominant theory of Alzheimer disease pathogenesis, it is not without debate. Not all individuals with substantial amyloid deposits develop clinical symptoms of dementia. This suggests that additional factors – including tau pathology, neuroinflammation, and genetic predisposition – also play critical roles in disease progression.

References

Alzheimer's Association - 2023 Alzheimer Disease Facts and Figures. Alzheimers Dement. 2023.
Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353-356.
World Health Organization (WHO) - Global status report on the public health response to dementia. Geneva: WHO; 2021.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.